FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini; Fotios Loupakis; Carlotta Antoniotti; Cristiana Lupi; Elisa Sensi; Sara Lonardi; Silvia Mezi; Gianluca Tomasello; Monica Ronzoni; Alberto Zaniboni; Giuseppe Tonini; Chiara Carlomagno; Giacomo Allegrini; Silvana Chiara; Mauro D'Amico; Cristina Granetto; Marina Cazzaniga; Luca Boni; Gabriella Fontanini; Alfredo Falcone

doi:10.1016/s1470-2045(15)00122-9

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00122-9 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1306-1315 ◽

Cited By ~ 398

Author(s):

Chiara Cremolini ◽

Fotios Loupakis ◽

Carlotta Antoniotti ◽

Cristiana Lupi ◽

Elisa Sensi ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Molecular Subgroup ◽

Subgroup Analyses ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725768305.793550889 ◽

2018 ◽

Author(s):

Sebastian Stintzing

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Molecular Subgroup ◽

Subgroup Analyses ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70330-4 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1065-1075 ◽

Cited By ~ 881

Author(s):

Volker Heinemann ◽

Ludwig Fischer von Weikersthal ◽

Thomas Decker ◽

Alexander Kiani ◽

Ursula Vehling-Kaiser ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30436-8 ◽

2020 ◽

Vol 21 (12) ◽

pp. 1563-1573 ◽

Cited By ~ 3

Author(s):

Thomas Powles ◽

Elizabeth R Plimack ◽

Denis Soulières ◽

Tom Waddell ◽

Viktor Stus ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(19)32222-6 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1929-1939 ◽

Cited By ~ 172

Author(s):

Luis Paz-Ares ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3715466 ◽

2020 ◽

Author(s):

Biyun Wang ◽

Tao Sun ◽

Yannan Zhao ◽

Shusen Wang ◽

Jian Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.013 ◽

2021 ◽

Vol 154 ◽

pp. 296-306

Author(s):

Tadamichi Denda ◽

Atsuo Takashima ◽

Makio Gamoh ◽

Ichiro Iwanaga ◽

Yoshito Komatsu ◽

...

Keyword(s):

Colorectal Cancer ◽

Primary Tumour ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Tumour Location ◽

Ras Status ◽

First Line Treatment

Download Full-text

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30608-3 ◽

2017 ◽

Vol 18 (11) ◽

pp. 1454-1466 ◽

Cited By ~ 300

Author(s):

Yi-Long Wu ◽

Ying Cheng ◽

Xiangdong Zhou ◽

Ki Hyeong Lee ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3730 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3730-3730

Author(s):

G. Zhongzhen ◽

F. Fengyi ◽

L. Xiaoqing ◽

W. Yajie ◽

Y. Baoming ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Oral Capecitabine ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30539-8 ◽

2021 ◽

Vol 22 (1) ◽

pp. 51-65 ◽

Cited By ~ 1

Author(s):

Jonathan W Goldman ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Annals of Oncology ◽

10.1093/annonc/mdx816 ◽

2018 ◽

Vol 29 (3) ◽

pp. 624-631 ◽

Cited By ~ 21

Author(s):

Y. Yamada ◽

T. Denda ◽

M. Gamoh ◽

I. Iwanaga ◽

S. Yuki ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Noninferiority Trial ◽

Open Label Phase ◽

First Line Treatment

Download Full-text